Chapter 1. Introduction


1.1. Report description and scope

1.2. Research scope

1.3. Research methodology


1.3.1. Market research process

1.3.2. Market research methodology

Chapter 2. Executive Summary


2.1. Global cancer drugs market, 2015  2021 (USD Billion)

2.2. Global cancer drugs market : Snapshot

Chapter 3. Cancer drugs Market Dynamics


3.1. Introduction

3.2. Market drivers


3.2.1. Global cancer drugs market drivers: Impact analysis

3.2.2. Rising incidences of target disease

3.2.3. Expiration of patents

3.3. Market restraints


3.3.1. Global cancer drugs market restraints: Impact analysis

3.3.2. High price of drug development

3.4. Opportunities


3.4.1. Increasing focus on personalized medicine

3.5. Porters five forces analysis


3.5.1. Bargaining power of suppliers

3.5.2. Bargaining power of buyers

3.5.3. Threat from new entrants

3.5.4. Threat from new substitutes

3.5.5. Degree of competition

3.6. Market attractiveness analysis


3.6.1. Market attractiveness analysis, by therapy segment

3.6.2. Market attractiveness analysis, by cancer type segment

3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Cancer Drugs Market  Competitive Landscape


4.1. Company Market Share Analysis


4.1.1. Global cancer Drugs market: company market share, 2015

4.2. Strategic Development


4.2.1. Acquisitions  Mergers

4.2.2. New Therapy Launch

4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures

4.2.4. Research and Development, Therapy and Regional Expansion

4.3. Price Trend Analysis

4.4. Therapy Portfolio

4.5. Patent Analysis (2011-2016)


4.5.1. Patent Trend

4.5.2. Patent Share by company

4.5.3. By Region

Chapter 5. Global Cancer drugs Market  Therapy Segment Analysis


5.1. Global cancer drugs market: Therapy overview


5.1.1. Global cancer drugs market revenue share, by Therapy, 2015 and 2021

5.2. Immunotherapy


5.2.1. Global Immunotherapy market , 2015  2021(USD Billion)

5.3. Targeted Therapy


5.3.1. Global Targeted Therapy market , 2015  2021(USD Billion)

5.4. Chemotherapy


5.4.1. Global Chemotherapy market , 2015  2021(USD Billion)

5.5. Hormone Therapy


5.5.1. Global Hormone Therapy market , 2015  2021(USD Billion)

5.6. Others


5.6.1. Global Others market , 2015  2021(USD Billion)

Chapter 6. Global Cancer Drugs Market  Cancer type Segment Analysis


6.1. Global cancer drugs market: Cancer type overview


6.1.1. Global cancer drugs market revenue share, by cancer type, 2015 and 2020

6.2. Breast Cancer


6.2.1. Global cancer drugs market for Breast Cancer, 2015  2021 (USD Billion)

6.3. Blood Cancer


6.3.1. Global cancer drugs market for Blood Cancer, 2015  2021(USD Billion)

6.4. Gastrointestinal Cancer


6.4.1. Global cancer drugs market for Gastrointestinal Cancer, 2015  2021 (USD Billion)

6.5. Prostate Cancer


6.5.1. Global cancer drugs market for Prostate Cancer, 2015 - 2021(USD Billion)

6.6. Skin Cancer


6.6.1. Global cancer drugs market for Skin Cancer, 2015 - 2021(USD Billion)

6.7. Lung Cancer


6.7.1. Global cancer drugs market for Lung Cancer, 2015 - 2021(USD Billion)

6.8. Others


6.8.1. Global cancer drugs market for other cancer type , 2015  2021 (USD Billion)

Chapter 7. Global Cancer drugs Market  Regional Segment Analysis


7.1. Global cancer drugs market: Regional overview


7.1.1. Global cancer drugs market revenue share, by region, 2015 and 2021

7.2. North America


7.2.1. North America cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.2.2. North America cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.2.3. U.S.


7.2.3.1. U.S. cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.2.3.2. U.S. cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.3. Europe


7.3.1. Europe cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.3.2. Europe cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.3.3. Germany


7.3.3.1. Germany cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.3.3.2. Germany cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.3.4. France


7.3.4.1. France cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.3.4.2. France cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.3.5. UK


7.3.5.1. UK cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.3.5.2. UK cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.4. Asia Pacific


7.4.1. Asia Pacific cancer drugs market revenue, by Therapy, 2015  2021, (USD Billion)

7.4.2. Asia Pacific cancer drugs market revenue, by cancer type, 2015  2021, (USD Billion)

7.4.3. China


7.4.3.1. China cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.4.3.2. China cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.4.4. Japan


7.4.4.1. Japan cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.4.4.2. Japan cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.4.5. India


7.4.5.1. India cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.4.5.2. India cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.5. Latin America


7.5.1. Latin America cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.5.2. Latin America cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

7.5.3. Brazil


7.5.3.1. Brazil cancer drugs market revenue, by Therapy, 2015  2021(USD Billion)

7.5.3.2. Brazil cancer drugs market revenue, by cancer type, 2015  2021 (USD Billion)

7.6. Middle East and Africa


7.6.1. Middle East and Africa cancer drugs market revenue, by Therapy, 2015  2021 (USD Billion)

7.6.2. Middle East and Africa cancer drugs market revenue, by cancer type, 2015  2021(USD Billion)

Chapter 8. Company Profile


8.1. Bayer


8.1.1. Overview

8.1.2. Financials

8.1.3. Therapy portfolio

8.1.4. Business strategy

8.1.5. Recent developments

8.2. GlaxoSmithKline


8.2.1. Overview

8.2.2. Financials

8.2.3. Therapy portfolio

8.2.4. Business strategy

8.2.5. Recent developments

8.3. Novartis


8.3.1. Overview

8.3.2. Financials

8.3.3. Therapy portfolio

8.3.4. Business strategy

8.3.5. Recent developments

8.4. Sanofi


8.4.1. Overview

8.4.2. Financials

8.4.3. Therapy portfolio

8.4.4. Business strategy

8.4.5. Recent developments

8.5. Pfizer


8.5.1. Overview

8.5.2. Financials

8.5.3. Therapy portfolio

8.5.4. Business strategy

8.5.5. Recent developments

8.6. Amgen


8.6.1. Overview

8.6.2. Financials

8.6.3. Therapy portfolio

8.6.4. Business strategy

8.6.5. Recent developments

8.7. Merck


8.7.1. Overview

8.7.2. Financials

8.7.3. Therapy portfolio

8.7.4. Business strategy

8.7.5. Recent developments

8.8. Bristol-Myers Squibb


8.8.1. Overview

8.8.2. Financials

8.8.3. Therapy portfolio

8.8.4. Business strategy

8.8.5. Recent developments

8.9. Celgene Corporation


8.9.1. Overview

8.9.2. Financials

8.9.3. Therapy portfolio

8.9.4. Business strategy

8.9.5. Recent developments

8.10. Ariad Pharmaceuticals


8.10.1. Overview

8.10.2. Financials

8.10.3. Therapy portfolio

8.10.4. Business strategy

8.10.5. Recent developments

8.11. Eli Lilly


8.11.1. Overview

8.11.2. Financials

8.11.3. Therapy portfolio

8.11.4. Business strategy

8.11.5. Recent developments

8.12. Hoffmann-La Roche Ltd


8.12.1. Overview

8.12.2. Financials

8.12.3. Therapy portfolio

8.12.4. Business strategy

8.12.5. Recent developments

8.13. Boehringer Ingelheim GmbH


8.13.1. Overview

8.13.2. Financials

8.13.3. Therapy portfolio

8.13.4. Business strategy

8.13.5. Recent developments

8.14. Johnson and Johnson


8.14.1. Overview

8.14.2. Financials

8.14.3. Therapy portfolio

8.14.4. Business strategy

8.14.5. Recent developments

8.15. Teva Pharmaceuticals


8.15.1. Overview

8.15.2. Financials

8.15.3. Therapy portfolio

8.15.4. Business strategy

8.15.5. Recent developments